Blueprint Medicines Co. (NASDAQ:BPMC) Shares Sold by Schonfeld Strategic Advisors LLC

Schonfeld Strategic Advisors LLC trimmed its position in shares of Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) by 77.8% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 13,200 shares of the biotechnology company's stock after selling 46,158 shares during the period. Schonfeld Strategic Advisors LLC's holdings in Blueprint Medicines were worth $1,151,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Torray Investment Partners LLC boosted its stake in shares of Blueprint Medicines by 1.1% during the 4th quarter. Torray Investment Partners LLC now owns 16,499 shares of the biotechnology company's stock worth $1,439,000 after purchasing an additional 186 shares during the period. Franklin Resources Inc. boosted its stake in shares of Blueprint Medicines by 0.7% during the 3rd quarter. Franklin Resources Inc. now owns 36,761 shares of the biotechnology company's stock worth $3,259,000 after purchasing an additional 265 shares during the period. Summit Investment Advisors Inc. boosted its stake in shares of Blueprint Medicines by 4.4% during the 4th quarter. Summit Investment Advisors Inc. now owns 6,652 shares of the biotechnology company's stock worth $580,000 after purchasing an additional 283 shares during the period. Pitcairn Co. boosted its stake in shares of Blueprint Medicines by 2.8% during the 4th quarter. Pitcairn Co. now owns 10,608 shares of the biotechnology company's stock worth $925,000 after purchasing an additional 293 shares during the period. Finally, Hillsdale Investment Management Inc. boosted its stake in shares of Blueprint Medicines by 0.6% during the 4th quarter. Hillsdale Investment Management Inc. now owns 50,830 shares of the biotechnology company's stock worth $4,433,000 after purchasing an additional 310 shares during the period.

Blueprint Medicines Stock Performance

Shares of NASDAQ BPMC traded down $0.49 during midday trading on Tuesday, reaching $99.82. The company had a trading volume of 220,212 shares, compared to its average volume of 778,347. The business's 50-day simple moving average is $88.70 and its 200 day simple moving average is $94.01. The stock has a market cap of $6.45 billion, a P/E ratio of -92.43 and a beta of 0.83. Blueprint Medicines Co. has a 1 year low of $73.04 and a 1 year high of $121.90. The company has a current ratio of 2.85, a quick ratio of 2.80 and a debt-to-equity ratio of 1.15.

Blueprint Medicines (NASDAQ:BPMC - Get Free Report) last posted its quarterly earnings results on Thursday, May 1st. The biotechnology company reported ($0.74) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.42) by ($0.32). The company had revenue of $149.41 million during the quarter, compared to analysts' expectations of $158.31 million. Blueprint Medicines had a negative return on equity of 77.49% and a negative net margin of 13.19%. The company's quarterly revenue was up 55.5% on a year-over-year basis. During the same period in the prior year, the business posted $1.40 EPS. On average, analysts forecast that Blueprint Medicines Co. will post -1.28 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms recently commented on BPMC. StockNews.com raised shares of Blueprint Medicines from a "sell" rating to a "hold" rating in a research note on Friday, May 2nd. Wolfe Research began coverage on shares of Blueprint Medicines in a research report on Tuesday, March 18th. They issued an "outperform" rating for the company. HC Wainwright reissued a "buy" rating and issued a $135.00 price objective on shares of Blueprint Medicines in a research report on Friday, May 2nd. Wedbush reissued an "outperform" rating and issued a $128.00 price objective on shares of Blueprint Medicines in a research report on Thursday, May 1st. Finally, Needham & Company LLC reduced their price target on shares of Blueprint Medicines from $133.00 to $130.00 and set a "buy" rating for the company in a report on Monday, April 28th. Five research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, Blueprint Medicines presently has an average rating of "Moderate Buy" and a consensus price target of $126.56.

Insiders Place Their Bets

In related news, insider Ariel Hurley sold 2,752 shares of the firm's stock in a transaction on Monday, May 5th. The shares were sold at an average price of $103.13, for a total transaction of $283,813.76. Following the sale, the insider now owns 16,944 shares in the company, valued at approximately $1,747,434.72. This trade represents a 13.97% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, COO Christina Rossi sold 2,274 shares of the stock in a transaction on Monday, May 5th. The shares were sold at an average price of $101.75, for a total transaction of $231,379.50. Following the transaction, the chief operating officer now directly owns 66,992 shares in the company, valued at approximately $6,816,436. The trade was a 3.28% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 10,503 shares of company stock valued at $1,027,931. Insiders own 4.21% of the company's stock.

Blueprint Medicines Company Profile

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.